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Abstract
We show that, under some plausible assumptions, the gain in QALYs a screening program
offers is a positive linear transformation of the program’s sensitivity level. This result
simplifies considerably the cost−utility analysis of mutually exclusive screening programs.
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Cost—utility analyses (CUAs) that measure cost-eﬀectiveness in costs per
quality-adjusted life-year (QALY) have increasingly become the standard in
the economic evaluation of health care programs (e.g., Neumann et al., 1996).
The US Public Health Service’s Panel on Cost-Eﬀectiveness in Health and
Medicine has recommended that, for analyses intended to inform resource al-
location, a reference case should be included that measures cost-eﬀectiveness
as incremental costs/QALY, also known as incremental CU ratios (e.g., Gold
et al., 1996).
However, the collection of utility data to quality-adjust years of life can be
expensive and resource-intensive. Furthermore, there is no consensus about
the method to be used to elicit health state utility weights (e.g., Bleichrodt
and Johannesson, 1997; Bleichrodt, 2002) or about the discount rate to be
used to obtain present values of future health beneﬁts (e.g., Bleichrodt and
Gafni, 1996; Cairns and van der Pol, 2000).
We show here that for an interesting class of health care programs, the
so-called screening programs, incremental CU ratios can be obtained without
the computation of QALYs, provided programs satisfy some mild assump-
tions. More precisely, we show that under three assumptions, the gain in
QALYs a screening program oﬀers is a positive linear transformation of an
intrinsic property of the program, namely, the ability of the program to iden-
tify correctly those who have the disease. This allows circumventing the
problems described above, besides of simplifying the analysis considerably.
2T h e m o d e l
Screening is traditionally deﬁned as testing a population of asymptomatic in-
dividuals to identify precursors of a disease. The subjects who test positive
are sent on for further evaluation in a subsequent diagnostic test to determine
whether they do, in fact, have the disease. Individuals can be partitioned
into four groups (true positives, false positives, true negatives and false neg-
atives), according to whether they do or do not have the disease and whether
their screening tests are positive or negative. We can compute how likely an
individual would belong to each of the four groups by using characteristics
of the population (prevalence of the disease) and of the detection ability of
the screening test (sensitivity and speciﬁcity). Prevalence (ρ)i st h ep r o b -
ability of an individual in the population being impaired. The sensitivity
of the screening test (π1) is the conditional probability that an individual
with the disease is positively detected by the test. The speciﬁcity of the
2test (π2) is the conditional probability of an individual without the disease
being correctly detected as negative in the test. Using these deﬁnitions, the
probability of an individual being a true negative ((1−ρ)π2), a true positive
(ρπ1), a false positive ((1 − ρ)(1 − π2)) and a false negative (ρ(1 − π1))c a n
be easily expressed.
Let S = {s1,...,sm} be the set of mutually exclusive screening programs
that are available for the early detection of a given disease. For all sj ∈ S,l e t






In a CUA, the cost-eﬀectiveness is measured in costs-per-QALY-gained
(CU) ratios. Let Q be the QALY index that gives for each individual health
proﬁle its number of QALYs.2 L e tu sd e n o t eb yGTP
j the group of true posi-




the group of false positive (false negative) [true negative] individuals after im-
plementing sj.F o re a c hk ∈ {TP,FP,FN,TN},l e tQk
j denote the expected
number of QALYs for an individual in group Gk
j and ρk
j the probability of
being in Gk
j. Then, the expected number of QALYs for an individual, af-




j.T h u s , f o r si,s j ∈ S,t h e i r
incremental CU ratio is given by
ci−cj
Qi−Qj.
3T h e r e s u l t
We show in this section that, for some screening programs, CU ratios and
CS ratios are essentially equivalent . More precisely, we show that for screen-
ing programs satisfying three assumptions, a CU ratio is a (positive) linear
transformation of the corresponding CS ratio.
The ﬁrst assumption says, roughly, that utility does not decrease ‘per
se’ by being referred to a screening program. In other words, the expected
QALYs of a true (false) negative do not depend on the particular screening
program being implemented. The second assumption says that early de-
tection of the disease is advantageous at an individual level, and that this
individual improvement is independent of the screening method chosen. The
third assumption says that there are no utility diﬀerences between healthy
individuals with diﬀerent test results, i.e., between a false positive and a true
negative individual. Formally,
1By costs we mean all sort of health care expenses associated with the program, such
as the costs of the screening technique, and the costs of the ﬁnal diagnostic test to which
every individual that has been identiﬁed as positive by the screening is referred. Thus,
the sensitivity and the speciﬁcity of the program inﬂuence its costs, i.e., cj = cj(π1
j,π2
j).
2Note that Q depends on the particular elicitation method and discount rate chosen.
3Assumption 1: For each QALY index Q,a n df o ra l lsj ∈ S, we have
Q
TN
j = Q, and Q
FN
j = b Q.
Assumption 2: For each QALY index Q,a n df o ra l lsj ∈ S, there exists












The plausibility of these assumptions depends on the screening programs
we are considering. They are fulﬁlled whenever the alternative programs
are non-invasive and such that false positives are correctly identiﬁed in a
short period of time. For instance, in the case of newborn and non-invasive
screening programs, the three assumptions are sound.3
We now have the following result:
Theorem 1 Under Assumptions 1 to 3, the incremental CU ratios are a
(positive) linear transformation of the corresponding incremental CS ratios.
Proof.
Fix si,s j ∈ S and a QALY index Q.F o rk = i,j, the expected number


















Hence, the incremental utility from si to sj is
































































































3See Herrero and Moreno-Ternero (2005) for further details in the particular case of
newborn hearing screening programs.

























































where k = k(ρ,Q)= 1
ρ·γQ > 0.N o t et h a tk is not screening method-speciﬁc.
This says, in particular, that the order of incremental CU ratios coincides
with the order of incremental CS ratios.4
4 Discussion
The ﬁrst step in using CUA for mutually exclusive programs is to exclude
those programs that are strictly dominated, i.e., those for which there exists
another available program more eﬀective (i.e., providing more QALYs) and
less expensive (e.g., Weinstein, 1990). By Theorem 1, this simply means
excluding programs that are more expensive and less sensitive than another
available program (see footnote 4).
The second step is to rank programs according to their eﬀectiveness (i.e.,
number of QALYs they provide) and then compute the incremental CU ratio
for each successively more eﬀective program. If any of these incremental ra-
tios turns out to be less than the previous one in the sequence of increasingly
eﬀective mutually exclusive programs, then the less eﬀective one is ruled out
by extended dominance, and it should never be implemented irrespective of
the amount of resources available (e.g., Garber, 2000). This algorithm re-
sults in a sequence of programs with increasing incremental cost-eﬀectiveness
r a t i o s .T h eo p t i m a ld e c i s i o nr u l ei st om o v eu pt h el i s to fi n c r e m e n t a lr a t i o s
and implement successively more eﬀective (and expensive) programs until
the resources are exhausted (e.g., Johannesson and Weinstein, 1993).5
4Note also that the ranking of programs according to the QALYs they provide coincides




5This decision rule applies under the assumption of divisibility of programs with con-
stant returns to scale (e.g., Birch and Gafni, 1992). See Elbasha and Messonnier (2004)
for the resulting rule after relaxing this assumption.
5By Theorem 1, we can simplify this algorithm as follows. First, rank pro-
grams according to their sensitivity levels. Then, calculate the incremental
CS ratio for each successively more sensitive program. Ruling out programs
by extended dominance, this alternative algorithm results in a sequence of
programs with increasing incremental CS ratios. The optimal decision rule
would be to move up the list of incremental ratios and implement successively
more sensitive (and expensive) programs until resources are exhausted. The-
orem 1 guarantees that both algorithms produce the same outcomes.
We acknowledge, however, that the alternative algorithm just presented
is only valid for the case of mutually exclusive programs and it could not
be used for most general decision contexts in which a number of clusters of
m u t u a l l ye x c l u s i v ep r o g r a m si sc o n s i d e r e d . 6
The alternative algorithm just described only uses statistical properties
of each screening program. This resembles the main method in the literature
on the measurement of the accuracy of diagnostic systems: the so-called
ROC analyses (e.g., Sweets, 1988). A ROC analysis assesses the value of
diagnostic tests by deciding where to put the threshold when using the test.
This requires consideration on two factors: the total number of errors (type
I errors, or false negative cases, and type II errors, or false positive cases)
made, and the relative importance of errors. The threshold is chosen so that
we minimize the total error rate, i.e., the weighted aggregation of type I
errors and type II errors, where weights are chosen to reﬂect their relative
importance. Our Assumption 3 implies that the importance of false positives
is negligible. Thus, a ROC analysis of screening programs satisfying our
assumptions would also rank them according to their sensitivity levels. This
is precisely what we obtain from Theorem 1 in the case in which we rank
programs according to the QALYs they oﬀer.
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